EQ
Equillium Inc
Halal Rating :
Last Price
$0.64
Last updated:
Market Cap
-
7D Change
-7.97%
1 Year Change
-14.75%
Company Overview
Industries
Exchange
Next Earnings Date
Equillium, Inc. is a clinical-stage biotechnology company developing novel immunology therapeutics. The company's primary focus is on developing innovative treatments for severe autoimmune and inflammatory disorders. Their lead product candidate, itolizumab, is being developed for multiple indications including acute graft-versus-host disease (aGVHD), lupus nephritis, and uncontrolled asthma.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $12.16m | $12.84m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $13.85m | $13.95m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $10.69m | $13.48m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Equillium Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.